Form SC 13G HALOZYME THERAPEUTICS Filed by: BB BIOTECH AG
Tweet
Share
E-mail
http://archive.fast-edgar.com/20140807/AB22922FZ22ROJZ2222T2ZXSKMT4OZ223262
Filed on: August 7, 2014
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
- Halozyme expects minimal Medicare pricing impact on royalties through 2035
- Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029
Create E-mail Alert Related Categories
SEC FilingsRelated Entities
13GSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
